Journal
STEM CELLS
Volume 33, Issue 8, Pages 2400-2415Publisher
WILEY-BLACKWELL
DOI: 10.1002/stem.2053
Keywords
Glioma stem cells; Mesenchymal stem cells; Glioblastoma; Brain tumor; Interleukin-6; STAT3
Categories
Funding
- National Cancer Institute [CA115729, 1P50CA127001]
- Ben and Cathy Ivy Foundation
- Broach Foundation for Brain Cancer Research
- National Brain Tumor Foundation
- Collaborative Ependymoma Research Network (CERN)
- Gene Pennebaker Brain Cancer Fund
- Sorenson Foundation
- Brian McCulloch Fund
- CUREFEST Foundation (Bauman Fund)
- Elias Family Fund
- M.D. Anderson Center for Targeted Therapy
- NATIONAL CANCER INSTITUTE [R01CA115729, P50CA127001, P50CA083639, P30CA016672] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Although mesenchymal stem cells (MSCs) have been implicated as stromal components of several cancers, their ultimate contribution to tumorigenesis and their potential to drive cancer stem cells, particularly in the unique microenvironment of human brain tumors, remain largely undefined. Consequently, using established criteria, we isolated glioma-associated-human MSCs (GA-hMSCs) from fresh human glioma surgical specimens for the first time. We show that these GA-hMSCs are nontumorigenic stromal cells that are phenotypically similar to prototypical bone marrow-MSCs. Low-passage genomic sequencing analyses comparing GA-hMSCs with matched tumor-initiating glioma stem cells (GSCs) suggest that most GA-hMSCs (60%) are normal cells recruited to the tumor (group 1 GA-hMSCs), although, rarely (10%), GA-hMSCs may differentiate directly from GSCs (group 2 GA-hMSCs) or display genetic patterns intermediate between these groups (group 3 GA-hMSCs). Importantly, GA-hMSCs increase proliferation and self-renewal of GSCs in vitro and enhance GSC tumorigenicity and mesenchymal features in vivo, confirming their functional significance within the GSC niche. These effects are mediated by GA-hMSC-secreted interleukin-6, which activates STAT3 in GSCs. Our results establish GA-hMSCs as a potentially new stromal component of gliomas that drives the aggressiveness of GSCs, and point to GA-hMSCs as a novel therapeutic target within gliomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available